MINNEAPOLIS, April 30,
2024 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent
director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a
member of the Science and Technology Committee. Following the
appointment, the board of Bio-Techne will be temporarily comprised
of eleven directors, ten of whom are independent.
Dr. Klimovsky is currently the Executive Vice President and
Chief Development Officer at Genmab, an international biotechnology
company specialized in the creation and development of antibody
therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held
various senior global clinical and research positions at Novartis
Oncology, a division of Novartis AG, including SVP & Global
Head, Oncology Clinical Development. Dr. Klimovsky also served as
Regional Medical Director, Latin
America for Merck & Co. and held several research and
development roles of increasing responsibility at Bristol-Myers
Squibb Company. Dr. Klimovsky received her M.D. from the
Universidad de Buenos Aires.
Dr. Klimovsky previously (from 2018 to Feb 2024) served as a Director of Bellicum
Pharmaceuticals, a company discovering and developing novel
cellular immunotherapies for the treatment of hematological cancers
and solid tumors.
"We are pleased to welcome Dr. Klimovsky to our board," said
Bob Baumgartner, Chairman of the
Board of Bio-Techne. "She brings tremendous scientific and
international experience, including running large development
groups at global biopharma companies. She also has extensive
experience in Latin America, which
will bring important expertise as Bio-Techne continues to expand
globally."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
David Clair, Vice President,
Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-appoints-dr-judith-klimovsky-to-board-of-directors-302129811.html
SOURCE Bio-Techne Corporation